Synaptic Regeneration for Glaucoma Treatment: New Study Results
News Context
At a glance
- Here's a breakdown of the clinical trial facts from the provided text:
- * NCT05882695: A clinical trial for SPG302 in Amyotrophic Lateral sclerosis (ALS) and schizophrenia.
- * Preclinical studies suggest it may protect retinal ganglion cells by reversing synapse loss, possibly offering a new treatment for glaucoma and other retinal synaptopathies.
Here’s a breakdown of the clinical trial facts from the provided text:
* NCT05882695: A clinical trial for SPG302 in Amyotrophic Lateral sclerosis (ALS) and schizophrenia.
* NCT06442462: A phase 2 clinical trial for SPG302 in schizophrenia.
Key details about SPG302:
* it’s administered as a once-a-day pill.
* Preclinical studies suggest it may protect retinal ganglion cells by reversing synapse loss, possibly offering a new treatment for glaucoma and other retinal synaptopathies.